RSV Vaccine and Season Information: Who Should Get It
Written by Vic Allen · Owner
Who the RSV vaccine is recommended for, how much it has cut hospitalizations in older adults, and why it's a one-and-done shot for now.
RSV is a viral infection of the lower respiratory tract that affects people of all ages. The virus is very contagious and can cause severe respiratory symptoms that can last several weeks.
The condition can become much more severe in adults with chronic health problems such as heart or lung disease.
The RSV vaccine is recommended for everyone 75 years and older. Those ages 50 to 75 with health-related conditions that support protection should discuss the need with their provider or pharmacist.
Before the rollout of adult RSV vaccines (authorized in mid-2023), RSV caused roughly 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths annually among older U.S. adults. RSV vaccine statistics show that RSV-related hospitalizations decreased by over 70% in adults vaccinated after this initial roll-out.
Currently, the RSV vaccine is a one-and-done experience; however, outcomes since 2023 suggest protection wanes after vaccination, which may prompt a change in recommendations.
There are multiple vaccines available; the best advice is to discuss a vaccine plan with your provider or pharmacist.